Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 2/20 | 0.42 |
| ▸ | KDM5B | Q9UGL1 | 3/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | AXL | P30530 | 7/20 | 0.38 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.38 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.38 |
| ▸ | MERTK | Q12866 | 1/20 | 0.38 |
| ▸ | PLAU | P00749 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.37 |
| ▸ | CDK2 | P24941 | 1/20 | 0.37 |
| ▸ | TTK | P33981 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26698086 | 0.74 | CNR2 (0.49) | ADORA2AMAPTAXLLRRK2PLAU | |
| SCHEMBL3955630 | 0.74 | KDM4E (0.44) | ADORA2AMAPTMAPK1AXLPLAU | |
| SCHEMBL16341708 | 0.73 | ALDH1A1 (0.42) | LRRK2CDK2 | |
| SCHEMBL16561261 | 0.73 | JAK2 (0.44) | PIM1KDM5BADORA2AMAPK1AXL | |
| SCHEMBL14983673 | 0.73 | SIGMAR1 (0.44) | PIM1KDM5BAXLLRRK2 | |
| SCHEMBL16561353 | 0.73 | PIM1 (0.38) | PIM1KDM5BADORA2AMAPK1AXL | |
| SCHEMBL15984746 | 0.71 | ERN1 (0.44) | PIM1ADORA2AMAPTLRRK2FGFR3 | |
| SCHEMBL6069364 | 0.71 | CCNB2 (0.45) | ADORA2AMAPT | |
| SCHEMBL24713133 | 0.70 | LRRK2 (0.44) | PIM1MAPK1AXLLRRK2 | |
| SCHEMBL26242520 | 0.70 | PIM1 (0.39) | PIM1ADORA2AMAPK1AXLLRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9440970-B2 | Pyrazole derivative | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2016-09-13 | — | — | US | disclosed |
| US-20150133448-A1 | NOVEL PYRAZOLE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2015-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150133448-A1 | NOVEL PYRAZOLE DERIVATIVE | PDE10A, PDE3A, PDE5A | PIM1 2159/4885KDM5B 1133/4885ADORA2A 930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.